Vaccination by Inhalation
X-rays of COVID-19 exposed monkeys. The left monkey was treated with FLOVID-20. Under Development, FDA approval required
FLOVID-20
Treatment for new COVID-19 infections. Administered by inhaler. The mutation threat is growing. FLOVID-20 is designed to treat all known variants. Under Development, FDA Approval Required
The FlowVax Platform
A revolutionary targeted killer T-Cell immune system therapy (immunotherapy) platform validated by extensive animal testing in mice and macaques. Medicines that precisely treat cancer and viral disease with minimal side effects.
Stable Dry Powder
Multiple Delivery Pathways
For Virus – inhalation, intramuscular
For Cancer – intranodal, intramuscular
Quick disease-specific therapy creation. Rapid high-volume production capability.
Our Mission
Flow Pharma is dedicated to immunotherapy innovation.
Our exclusive technology and manufacturing expertise are poised to transform the treatment and prevention of cancer and viral disease.
Flovid-20
Flovid-20
An inhaled treatment to prevent COVID-19 disease in both virus-exposed and healthy patient populations..
FlowVax Ebola & Marburg
Ebola, Marburg
Marburg is a weaponized Ebola-like virus. By stimulating T-cells to target this virus, long-lasting infection prevention is attainable.
FlowVax BreastCA
Cancer
A revolutionary T-cell biomedicine that provides new hope for those with treatment-resistant, triple-negative breast cancer.
News & Press
Delta and Omicron Variants are Driving New Cases
Uncategorized
During the COVID-19 pandemic, new cases in the U.S. have repeatedly risen and dropped dramatically.
More Evidence for T-Cells: Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts
COVID-19
A new research paper led by the Imperial College London, published in the peer-reviewed journal nature communications, finds the following:.
The Peer Reviewed Journal Vaccines Published the Results of Flow Pharma’s COVID-19 Primate Study
Company Update, COVID-19, FLOVID-20
Flow Pharma, Inc., a San Francisco Bay Area biotechnology company developing the FlowVax™ peptide vaccine platform technology, today announced the publication of an article describing research performed at the University of Texas Medical Branch at Galveston (UTMB)
Natural variants in SARS-CoV-2 Spike protein pinpoint structural and functional hotspots with implications for prophylaxis and therapeutic strategies
Research Publications
In December 2019, a novel coronavirus, termed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was identified as the cause of pneumonia with severe respiratory distress and outbreaks in Wuhan, China.